Cargando…
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938196/ https://www.ncbi.nlm.nih.gov/pubmed/31920338 http://dx.doi.org/10.2147/OTT.S195552 |